CG Oncology, Inc. Common stock

NASDAQ:CGON

Biotechnology

Healthcare
$80.00 +2.23%

+$1.35 today

Market cap
$7.15B
Beta
0.31
P/E (TTM)
-28.0
EPS (TTM)
-$2.21
52W Low $23.65High $75.50

Volume 1.79M

Average 1.08M

CGON Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

CG Oncology, Inc. Common stockNASDAQ: CGON

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 88.87M shares rose 15.8% year over year, ahead of the +15.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +5.1% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +15.8% holds above the trailing-twelve-month pace of +15.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
88.87M+0.8% QoQ
Last fiscal yearDec 2025
77.3M+23.7% YoY
LTMSep 2026
84.72M+15.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.8%——
1 year+23.7%——
3-year CAGR+5.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
77.3M USD
Year-over-year change
+23.7%
4-year CAGR
+3.8%

Weighted Avg Shares (Diluted) vs competitors

How CGON compares with its peers on the latest reported figures

  • CGON's LTM Sep 2026 weighted avg shares (diluted) of 84.72M shares is the 2nd highest of the 3 companies compared; the peer median is 540.35M shares.
  • Its year-over-year change of +15.3% is the 2nd highest of 3, against a peer median of +16.3%.
  • Over three fiscal years its annual growth of +5.1% compares with a peer median of +30.1%.
CGON Competitors Peer median
Weighted Avg Shares (Diluted) for CGON and competitors
Company Period LTM YoY 3-year CAGR
IBRXImmunityBio, Inc.LTM Sep 20261.03B +20.6%+32.0%
CGONCG Oncology, Inc. Common stockLTM Sep 202684.72M +15.3%+5.1%
URGNUroGen Pharma Ltd.LTM Mar 202648.8M +11.9%+28.3%
Peer median (excluding CGON) 540.35M+16.3%+30.1%

Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.36M191K204K1.14M4.04M
Cost of Revenue10K15K45.75M82.1M4.65M
Gross Profit10.35M176K(45.55M)(80.96M)(607K)
Gross Margin99.9%92.1%-22327.5%-7108.3%-15.0%
Research & Development18.32M29.03M45.75M82.1M116.64M
Selling, General & Admin4.64M6.39M9.9M33.7M73.53M
Operating Expenses22.95M35.42M9.9M33.7M190.17M
Depreciation & Amortization10K15K17K32K1.45M
EBITDA(12.38M)(35.43M)(48.59M)(88.01M)(159.55M)
EBITDA Margin-119.5%-18548.2%-23818.6%-7726.7%-3949.3%
Operating Income(12.61M)(35.25M)(55.45M)(114.67M)(190.77M)
Operating Margin-121.7%-18453.4%-27180.9%-10067.3%-4722.1%
Interest Income006.9M26.62M29.93M
Interest Expense451K1K000
Other Income / Expenses(233K)(197K)6.84M26.63M29.78M
Income Before Tax(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Pre-Tax Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
Income Tax Expense00000
Net Income(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Net Margin-124.0%-18556.5%-23827.0%-7729.5%-3985.0%
EPS (Basic)(0.28)(0.66)(1.02)(1.41)(2.08)
EPS (Diluted)(0.28)(0.66)(1.02)(1.41)(2.08)
Weighted Avg Shares66.64M66.64M66.64M62.5M77.3M
Weighted Avg Shares (Diluted)66.64M66.64M66.64M62.5M77.3M

CG Oncology, Inc. Common stock

NASDAQ:CGON

Intrinsic Alpha fair value

Locked

Current Price

$80.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.